bioMérieux S.A. (LON:0RUG)

London flag London · Delayed Price · Currency is GBP · Price in EUR
112.70
0.00 (0.00%)
At close: Apr 22, 2025
11.92%
Market Cap 11.46B
Revenue (ttm) 3.29B
Net Income (ttm) 357.42M
Shares Out n/a
EPS (ttm) 3.01
PE Ratio 32.05
Forward PE n/a
Dividend 0.72 (0.64%)
Ex-Dividend Date Jun 9, 2025
Volume 3,645
Average Volume 20,590
Open 113.80
Previous Close n/a
Day's Range 112.40 - 113.80
52-Week Range 72.93 - 92.27
Beta 0.53
RSI 47.51
Earnings Date Sep 4, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; V... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1963
Employees 14,754
Stock Exchange London Stock Exchange
Ticker Symbol 0RUG
Full Company Profile

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.